BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23320868)

  • 1. Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient.
    Andic N; Gunduz E; Akay OM; Şahin D; Teke HÜ
    Platelets; 2014; 25(1):69-70. PubMed ID: 23320868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag in chronic idiopathic thrombocytopenic purpura.
    Panzer S; Pabinger I
    Lancet; 2009 Feb; 373(9664):607-8. PubMed ID: 19231614
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustaining platelet counts in chronic ITP.
    Nurden AT
    Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056
    [No Abstract]   [Full Text] [Related]  

  • 6. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
    Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
    N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two new drugs for chronic ITP.
    Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag in thrombocytopenia.
    Zimmer J; Hentges F; Andrès E
    N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
    [No Abstract]   [Full Text] [Related]  

  • 9. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
    Dmytrijuk A; Robie-Suh K; Rieves D; Pazdur R
    Oncology (Williston Park); 2009 Nov; 23(13):1171-7. PubMed ID: 20043468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag--an oral thrombopoietin agonist.
    Sharma V; Randhawa H; Sharma A; Aggarwal S
    Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
    Özdemirkıran F; Payzın B; Kiper HD; Kabukçu S; Akgün Çağlıyan G; Kahraman S; Sevindik ÖG; Ceylan C; Kadıköylü G; Şahin F; Keskin A; Arslan Ö; Özcan MA; Kabukçu G; Görgün G; Bolaman Z; Büyükkeçeci F; Bilgir O; Alacacıoğlu İ; Vural F; Tombuloğlu M; Gökgöz Z; Saydam G
    Turk J Haematol; 2015 Dec; 32(4):323-8. PubMed ID: 25914025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of chronic myelogenous leukemia during treatment with TPO receptor agonist for ITP].
    Hattori H; Kuwayama M; Takamori H; Nishiura N; Karasuno T
    Rinsho Ketsueki; 2014 Dec; 55(12):2429-32. PubMed ID: 25744045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe cutaneous toxicity related to Eltrombopag.
    Meyer SC; Rovó A; Tsakiris DA; Scherer K; Tichelli A; Holbro A
    Br J Haematol; 2013 Feb; 160(3):412-4. PubMed ID: 23151239
    [No Abstract]   [Full Text] [Related]  

  • 14. Cortical vein thrombosis in a case of idiopathic thrombocytopenic purpura.
    Sahu KK; Varma SC
    Platelets; 2015; 26(4):374-5. PubMed ID: 24678621
    [No Abstract]   [Full Text] [Related]  

  • 15. Extensive cerebral venous sinus thrombosis following a dose increase in eltrombopag in a patient with idiopathic thrombocytopenic purpura.
    Mulla CM; Rashidi A; Levitov AB
    Platelets; 2014; 25(2):144-6. PubMed ID: 23320857
    [No Abstract]   [Full Text] [Related]  

  • 16. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale.
    Arnold DM; Jamula E; Heddle NM; Cook RJ; Hsia C; Sholzberg M; Lin Y; Kassis J; Blostein M; Larratt L; Amini S; Schipperus M; Carruthers J; Lane SJ; Li N; Kelton JG
    Thromb Haemost; 2019 Mar; 119(3):500-507. PubMed ID: 30685874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura.
    Noronha V; Philip SD; Joshi A; Prabhash K
    Int J Hematol; 2012 Sep; 96(3):380-2. PubMed ID: 22851056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
    Meyer O; Salama A
    Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol.
    Schiavotto C; Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):29-34. PubMed ID: 8039755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.